Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug tame ulcerative colitis?

NCT ID NCT05986136

Recruiting now Disease control Sponsor: Mostafa Bahaa Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug currently used for diabetes, can help control inflammation in people with mild-to-moderate ulcerative colitis. Researchers will give 50 adults either dapagliflozin plus standard mesalamine or mesalamine alone, and track changes in symptoms and colon inflammation. The goal is to see if adding dapagliflozin improves disease control without serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dapagliflozin (a diabetes drug) combined with mesalamine (a standard colitis drug)
What this could lead to
If it works, this could offer a new, well-tolerated treatment option for mild-to-moderate ulcerative colitis by reducing inflammation.
What could go wrong
This is a small, early-phase trial (50 people) testing a repurposed diabetes drug. It may not show significant benefit, and results may not apply to severe cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Faculty of Medicine, Mansoura University

    RECRUITING

    Al Mansurah, 7650001, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.